Evidence Summary
- Evidence Level
- Moderate
- Mechanism
- Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other
- Safety
- Nausea, insomnia, somnolence; significant CYP1A2 and CYP2C19 interactions. Avoid in combination with thioridazine, pimozide. Monitor for serotonin syndrome if combined with other serotonergics.
- Dosing
- 50–100 mg/day (often 100 mg); short courses (10–15 days) in early studies; some PASC protocols 4–8 weeks.
Sigma-1 + SSRI; early COVID + some Long COVID data. 50-100mg. CYP interactions, GI/insomnia. Preliminary for select symptoms; not core fatigue/autonomic first choice.
Clinical Trials
4 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT05874037 | Fluvoxamine for Long COVID-19 | Phase 2 | Completed |
| NCT07359482 | sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 | Phase 3 | Recruiting |
| NCT04510194 | COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) | Phase 3 | Completed |
| NCT06128967 | A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial | Phase 3 | Completed |
Key Studies / References
- See linked studies